Photo from Ajay Major/LinkedIn
Jul 31, 2024, 11:52
Ajay Major: PFS benefit in AMPLIFY Phase III trial in CLL
Ajay Major, Lymphoma Faculty at the CU School of Medicine, shared on X:
“Press release now out: PFS benefit in AMPLIFY Phase III trial of fixed-duration acala + venetoclax +/- obinutuzumab vs investigator choice of CIT. Would be great to have a 2nd-gen BTKi plus ven time-limited combo approved.”
Read further.
Source: Ajay Major/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 17:57
Nov 14, 2024, 17:46
Nov 14, 2024, 17:46
Nov 14, 2024, 17:42
Nov 14, 2024, 17:14